Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Christine Fisher

Concepts (257)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Uterine Cervical Neoplasms
15
2025
268
4.210
 Why?
Brachytherapy
13
2023
132
3.840
 Why?
Endometrial Neoplasms
10
2025
205
1.910
 Why?
Uterine Neoplasms
6
2025
98
1.670
 Why?
Breast Neoplasms
21
2026
2382
1.640
 Why?
Radiotherapy Planning, Computer-Assisted
7
2024
149
1.640
 Why?
Hysterectomy
5
2019
138
1.580
 Why?
Radiosurgery
5
2025
399
1.430
 Why?
Carcinosarcoma
3
2023
23
1.270
 Why?
Neoplasm Recurrence, Local
12
2026
1149
0.990
 Why?
Neoplasm Staging
20
2026
1471
0.960
 Why?
Genital Neoplasms, Female
4
2024
99
0.950
 Why?
Radiation Oncology
5
2022
82
0.940
 Why?
Databases, Factual
5
2021
1490
0.920
 Why?
Radiotherapy, Intensity-Modulated
2
2024
142
0.820
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2017
61
0.730
 Why?
Chemoradiotherapy
4
2019
239
0.720
 Why?
Radiotherapy, Adjuvant
6
2019
222
0.650
 Why?
Healthcare Disparities
2
2018
735
0.630
 Why?
Medical Oncology
7
2026
339
0.600
 Why?
Female
61
2026
78845
0.590
 Why?
Simulation Training
1
2021
135
0.590
 Why?
Ovarian Neoplasms
1
2025
595
0.580
 Why?
Margins of Excision
1
2019
50
0.560
 Why?
Aquaporin 4
1
2019
101
0.550
 Why?
Insurance, Health
2
2018
310
0.540
 Why?
Necrosis
1
2019
244
0.540
 Why?
Aged
27
2026
26153
0.500
 Why?
Antineoplastic Agents, Immunological
1
2019
198
0.490
 Why?
Middle Aged
31
2026
36215
0.480
 Why?
Insurance Coverage
1
2018
244
0.480
 Why?
Carcinoma, Neuroendocrine
1
2016
36
0.480
 Why?
Standard of Care
1
2016
81
0.470
 Why?
Humans
68
2026
145475
0.460
 Why?
Perioperative Care
1
2018
231
0.450
 Why?
SEER Program
6
2021
229
0.440
 Why?
Antineoplastic Combined Chemotherapy Protocols
6
2023
1963
0.440
 Why?
Mastectomy
4
2026
184
0.440
 Why?
Adenocarcinoma
4
2024
925
0.420
 Why?
Health Plan Implementation
1
2015
141
0.420
 Why?
Medical Errors
1
2015
119
0.410
 Why?
Survival Rate
7
2019
2090
0.410
 Why?
Carcinoma, Ductal, Breast
1
2014
89
0.400
 Why?
Radiotherapy Dosage
5
2023
288
0.400
 Why?
Neoplasms
3
2022
2906
0.390
 Why?
Quality Assurance, Health Care
1
2015
342
0.390
 Why?
Tumor Suppressor Protein p53
3
2023
534
0.380
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1443
0.380
 Why?
Carcinoma
1
2014
225
0.370
 Why?
Pelvis
1
2013
125
0.360
 Why?
Combined Modality Therapy
6
2020
1266
0.350
 Why?
Prostatectomy
1
2012
94
0.350
 Why?
Aged, 80 and over
13
2025
8333
0.350
 Why?
Adult
23
2026
40777
0.340
 Why?
Practice Patterns, Physicians'
2
2018
1371
0.340
 Why?
Vulvar Neoplasms
2
2024
13
0.330
 Why?
Internship and Residency
1
2021
1267
0.330
 Why?
Carcinoma, Endometrioid
2
2023
49
0.330
 Why?
Mastectomy, Segmental
4
2020
107
0.310
 Why?
Mutation
3
2023
4075
0.300
 Why?
United States
13
2022
16098
0.290
 Why?
Lymphatic Metastasis
3
2021
331
0.290
 Why?
Re-Irradiation
2
2020
9
0.280
 Why?
Cancer Pain
2
2018
39
0.260
 Why?
Prostatic Neoplasms
2
2012
978
0.250
 Why?
Vaginal Neoplasms
1
2026
19
0.240
 Why?
Sarcoma
2
2021
207
0.240
 Why?
Treatment Outcome
9
2023
11772
0.240
 Why?
Analgesics, Opioid
3
2021
1149
0.230
 Why?
Retrospective Studies
14
2024
17291
0.230
 Why?
Consensus
2
2024
477
0.220
 Why?
Chemotherapy, Adjuvant
4
2021
423
0.220
 Why?
Regression Analysis
2
2019
1001
0.210
 Why?
Neoadjuvant Therapy
2
2018
465
0.210
 Why?
Stakeholder Participation
1
2025
84
0.200
 Why?
Follow-Up Studies
4
2018
5423
0.200
 Why?
Young Adult
8
2021
14219
0.200
 Why?
Prognosis
6
2023
4316
0.200
 Why?
Papillomavirus Infections
2
2019
344
0.200
 Why?
Quality of Life
2
2026
3204
0.190
 Why?
Adenocarcinoma, Clear Cell
1
2023
14
0.190
 Why?
Carcinoma, Renal Cell
2
2015
230
0.190
 Why?
Positron-Emission Tomography
1
2024
343
0.190
 Why?
Kaplan-Meier Estimate
4
2021
969
0.190
 Why?
Patient Participation
1
2026
439
0.180
 Why?
Tertiary Care Centers
1
2023
195
0.180
 Why?
Hodgkin Disease
2
2016
171
0.180
 Why?
Hydrocephalus
1
2023
111
0.180
 Why?
Colonic Neoplasms
1
2024
257
0.180
 Why?
Decision Support Techniques
1
2026
477
0.170
 Why?
Brain Neoplasms
2
2023
1329
0.170
 Why?
Mass Spectrometry
1
2025
730
0.170
 Why?
beta Catenin
2
2023
254
0.170
 Why?
Kidney Neoplasms
2
2015
413
0.160
 Why?
Carcinoma, Squamous Cell
2
2017
641
0.160
 Why?
Benchmarking
1
2021
191
0.160
 Why?
Cancer Care Facilities
1
2020
48
0.160
 Why?
High-Throughput Nucleotide Sequencing
1
2023
530
0.160
 Why?
Veterans
2
2022
1635
0.150
 Why?
Gestational Trophoblastic Disease
1
2019
6
0.150
 Why?
Benzodiazepines
1
2021
168
0.150
 Why?
Immunohistochemistry
1
2023
1716
0.150
 Why?
Magnetic Resonance Imaging
2
2024
3904
0.150
 Why?
Lymph Nodes
1
2021
503
0.140
 Why?
Triple Negative Breast Neoplasms
1
2021
218
0.140
 Why?
Communication
1
2025
975
0.140
 Why?
Practice Guidelines as Topic
2
2017
1581
0.140
 Why?
Referral and Consultation
1
2024
867
0.130
 Why?
Relative Biological Effectiveness
1
2017
4
0.130
 Why?
Pain Management
2
2018
410
0.130
 Why?
Patient Acceptance of Health Care
1
2024
881
0.130
 Why?
Proportional Hazards Models
2
2018
1327
0.130
 Why?
Radiotherapy, Conformal
1
2017
74
0.120
 Why?
Adolescent
5
2019
22530
0.120
 Why?
Breast
1
2017
156
0.120
 Why?
Neoplasms, Radiation-Induced
1
2016
100
0.120
 Why?
Logistic Models
2
2018
2134
0.120
 Why?
Antineoplastic Agents
3
2017
2214
0.120
 Why?
Radiotherapy Setup Errors
1
2015
3
0.120
 Why?
Tomography, X-Ray Computed
2
2024
2769
0.120
 Why?
Pancreatic Neoplasms
1
2024
928
0.110
 Why?
Machine Learning
1
2021
587
0.110
 Why?
Radiation Injuries
1
2017
149
0.110
 Why?
Propensity Score
1
2018
377
0.110
 Why?
Neoplasms, Second Primary
1
2016
102
0.110
 Why?
Neoplasm Grading
4
2019
310
0.110
 Why?
Quality Control
1
2015
161
0.110
 Why?
Medically Uninsured
1
2015
132
0.110
 Why?
Risk Reduction Behavior
1
2016
217
0.110
 Why?
Radiation Tolerance
1
2015
103
0.110
 Why?
Physicians
1
2023
955
0.110
 Why?
Drug Administration Schedule
1
2016
782
0.110
 Why?
Curriculum
1
2021
1070
0.110
 Why?
Checklist
1
2015
110
0.100
 Why?
Soft Tissue Neoplasms
1
2015
131
0.100
 Why?
Cancer Vaccines
2
2005
161
0.100
 Why?
Risk Factors
6
2020
10885
0.100
 Why?
Breast Neoplasms, Male
1
2013
29
0.100
 Why?
Case-Control Studies
2
2019
3623
0.100
 Why?
Skin Neoplasms
2
2024
849
0.100
 Why?
Internet
1
2018
689
0.100
 Why?
Clinical Competence
1
2021
1243
0.100
 Why?
Tumor Burden
1
2014
325
0.100
 Why?
Gene Expression Profiling
2
2017
1767
0.090
 Why?
Guideline Adherence
1
2017
586
0.090
 Why?
Neoplasm Invasiveness
1
2014
506
0.090
 Why?
Socioeconomic Factors
1
2017
1323
0.090
 Why?
Bone Neoplasms
1
2015
259
0.090
 Why?
Randomized Controlled Trials as Topic
1
2019
1747
0.090
 Why?
Biomarkers, Tumor
4
2023
1321
0.090
 Why?
Patient Safety
1
2015
356
0.090
 Why?
Poly-ADP-Ribose Binding Proteins
2
2023
33
0.090
 Why?
Peptide Fragments
2
2005
693
0.090
 Why?
DNA Polymerase II
2
2023
35
0.090
 Why?
Texas
1
2012
272
0.080
 Why?
Medicaid
1
2015
467
0.080
 Why?
Male
12
2024
72843
0.080
 Why?
Disease Management
1
2014
653
0.080
 Why?
Age Factors
1
2017
3342
0.080
 Why?
Quality Indicators, Health Care
2
2022
336
0.070
 Why?
Lung Neoplasms
1
2023
2664
0.070
 Why?
Registries
1
2018
2406
0.070
 Why?
Cohort Studies
3
2021
6013
0.070
 Why?
Melanoma
1
2015
759
0.070
 Why?
Survival Analysis
1
2012
1374
0.070
 Why?
Liver Neoplasms
1
2015
776
0.070
 Why?
Risk Assessment
2
2020
3747
0.070
 Why?
Epidemics
2
2018
96
0.060
 Why?
Fertility Preservation
2
2019
55
0.060
 Why?
Opioid-Related Disorders
3
2021
602
0.060
 Why?
Gynecology
2
2018
181
0.060
 Why?
Prospective Studies
4
2023
8057
0.060
 Why?
Medicare
2
2021
903
0.060
 Why?
Prevalence
1
2012
2865
0.050
 Why?
Prostate-Specific Antigen
1
2005
161
0.050
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2005
161
0.050
 Why?
Paget Disease, Extramammary
1
2024
4
0.050
 Why?
Radiotherapy
2
2015
204
0.050
 Why?
DNA Mismatch Repair
1
2023
53
0.050
 Why?
Information Seeking Behavior
1
2023
40
0.050
 Why?
Aromatase
1
2023
35
0.050
 Why?
Needles
1
2023
63
0.050
 Why?
Time Factors
4
2020
7123
0.040
 Why?
Surveys and Questionnaires
2
2026
6066
0.040
 Why?
Receptors, Estrogen
2
2016
401
0.040
 Why?
Focus Groups
1
2025
569
0.040
 Why?
Anthracyclines
1
2021
49
0.040
 Why?
Taxoids
1
2021
114
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
50
0.040
 Why?
Precision Medicine
1
2025
459
0.040
 Why?
Hospitals, University
1
2021
176
0.040
 Why?
Trastuzumab
1
2021
118
0.040
 Why?
Estrogens
1
2023
367
0.040
 Why?
Quinolines
1
2021
190
0.040
 Why?
Radiometry
1
2019
56
0.040
 Why?
Microsatellite Instability
1
2019
55
0.040
 Why?
Chemoradiotherapy, Adjuvant
1
2019
44
0.040
 Why?
Papanicolaou Test
1
2019
35
0.040
 Why?
Organ Sparing Treatments
1
2019
37
0.040
 Why?
Cervix Uteri
1
2019
50
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
108
0.030
 Why?
Radiotherapy, Image-Guided
1
2018
39
0.030
 Why?
Guidelines as Topic
1
2020
266
0.030
 Why?
Papillomaviridae
1
2019
116
0.030
 Why?
India
1
2018
213
0.030
 Why?
Neoplasm Metastasis
1
2020
688
0.030
 Why?
PTEN Phosphohydrolase
1
2019
165
0.030
 Why?
Equipment Design
1
2019
525
0.030
 Why?
United States Department of Veterans Affairs
1
2022
778
0.030
 Why?
Vagina
1
2019
203
0.030
 Why?
Organs at Risk
1
2017
37
0.030
 Why?
Statistics, Nonparametric
1
2017
428
0.030
 Why?
Predictive Value of Tests
1
2021
2121
0.030
 Why?
Skin Ulcer
1
2015
15
0.030
 Why?
HLA-A2 Antigen
2
2005
36
0.030
 Why?
Thoracic Neoplasms
1
2015
39
0.030
 Why?
Abdominal Neoplasms
1
2015
47
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2021
992
0.030
 Why?
Fibrosis
1
2017
559
0.030
 Why?
Societies, Medical
1
2019
899
0.030
 Why?
Odds Ratio
1
2017
1082
0.030
 Why?
Evidence-Based Medicine
1
2018
740
0.030
 Why?
Reoperation
1
2017
633
0.030
 Why?
Clinical Decision-Making
1
2017
363
0.020
 Why?
Disease Progression
2
2015
2864
0.020
 Why?
Biopsy
1
2017
1082
0.020
 Why?
Confidence Intervals
1
2013
330
0.020
 Why?
Age Distribution
1
2013
403
0.020
 Why?
Sex Distribution
1
2013
387
0.020
 Why?
Membrane Proteins
1
2019
1164
0.020
 Why?
Receptors, Progesterone
1
2013
243
0.020
 Why?
Skin
1
2017
753
0.020
 Why?
Comorbidity
1
2017
1661
0.020
 Why?
Clinical Trials as Topic
1
2017
1061
0.020
 Why?
Vinblastine
1
2011
75
0.020
 Why?
Dacarbazine
1
2011
100
0.020
 Why?
Analysis of Variance
1
2013
1300
0.020
 Why?
Remission Induction
1
2011
307
0.020
 Why?
Colorado
1
2020
4554
0.020
 Why?
Mass Screening
1
2019
1360
0.020
 Why?
Bleomycin
1
2011
255
0.020
 Why?
Algorithms
1
2017
1845
0.020
 Why?
Doxorubicin
1
2011
401
0.020
 Why?
Sex Factors
1
2013
2105
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2378
0.020
 Why?
Incidence
1
2013
2923
0.020
 Why?
Pregnancy
1
2019
7202
0.020
 Why?
Cytotoxicity Tests, Immunologic
1
2005
39
0.010
 Why?
Cytotoxicity, Immunologic
1
2005
224
0.010
 Why?
T-Lymphocytes, Cytotoxic
1
2005
177
0.010
 Why?
Cross-Sectional Studies
1
2015
5905
0.010
 Why?
Immunoconjugates
1
2005
138
0.010
 Why?
Leukocytes, Mononuclear
1
2005
574
0.010
 Why?
Interferon-gamma
1
2005
784
0.010
 Why?
CD8-Positive T-Lymphocytes
1
2005
919
0.010
 Why?
Cell Line, Tumor
1
2005
3542
0.010
 Why?
Child
1
2013
22707
0.010
 Why?
Fisher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (257) concept(s)
_
Co-Authors Expand Description
See all (48) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)